{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:33:06Z","timestamp":1783038786370,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019650","name":"Vir Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cgh.2020.08.064","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T23:44:09Z","timestamp":1599003849000},"page":"1950-1958.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B"],"prefix":"10.1016","volume":"19","author":[{"given":"Hye Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Kit","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-9410","authenticated-orcid":false,"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.08.064_bib1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.064_bib2","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic Hepatitis B Infection: A Review","volume":"319","author":"Tang","year":"2018","journal-title":"Jama"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2020.08.064_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.12395","article-title":"Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?","volume":"34","author":"Calvaruso","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.08.064_bib4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.08.064_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.064_bib6","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.08.064_bib7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2016.06.021","article-title":"Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices","volume":"65","author":"Maurice","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib9","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/hep.29363","article-title":"Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease","volume":"66","author":"Augustin","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.08.064_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2013.09.029","article-title":"Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B","volume":"60","author":"Wong","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.27735","article-title":"Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis","volume":"61","author":"Kim","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.08.064_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2893.2008.01037.x","article-title":"Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B","volume":"16","author":"Chan","year":"2009","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2020.08.064_bib14","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/ajg.2012.331","article-title":"Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease","volume":"107","author":"Wong","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.08.064_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib16","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"D'Amico","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.08.064_bib17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1365-2036.2010.04473.x","article-title":"The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study","volume":"32","author":"Fleming","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.08.064_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2020.08.064_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D'Amico","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.064_bib21","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.08.064_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib23","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","article-title":"Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis","volume":"353","author":"Groszmann","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.08.064_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D'Amico","year":"1986","journal-title":"Dig Dis SCI"},{"key":"10.1016\/j.cgh.2020.08.064_bib25","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.08.064_bib26","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2015.06.006","article-title":"The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study","volume":"63","author":"Lampertico","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib27","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.08.064_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.08.064_bib29","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.29321","article-title":"Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population","volume":"66","author":"Choi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.08.064_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.gastro.2013.02.002","article-title":"Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment","volume":"144","author":"Wong","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.08.064_bib31","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.08.064_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2019.01.044","article-title":"Long-Term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520312234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520312234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:35:52Z","timestamp":1761543352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520312234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1542356520312234"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.08.064","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.08.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}